Harbor Capital Advisors Inc. Sells 4,052 Shares of Enfusion, Inc. (NYSE:ENFN)

Harbor Capital Advisors Inc. lowered its holdings in shares of Enfusion, Inc. (NYSE:ENFN) by 34.1% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 7,835 shares of the company’s stock after selling 4,052 shares during the period. Harbor Capital Advisors Inc.’s holdings in Enfusion were worth $81,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently bought and sold shares of ENFN. TenCore Partners LP bought a new position in shares of Enfusion during the 3rd quarter worth about $3,938,000. Dimensional Fund Advisors LP lifted its stake in Enfusion by 57.5% during the second quarter. Dimensional Fund Advisors LP now owns 524,142 shares of the company’s stock worth $4,466,000 after purchasing an additional 191,436 shares during the period. JPMorgan Chase & Co. boosted its holdings in Enfusion by 612.4% during the third quarter. JPMorgan Chase & Co. now owns 208,022 shares of the company’s stock valued at $1,974,000 after purchasing an additional 178,821 shares in the last quarter. Impax Asset Management Group plc boosted its holdings in Enfusion by 25.4% during the third quarter. Impax Asset Management Group plc now owns 676,948 shares of the company’s stock valued at $6,424,000 after purchasing an additional 136,948 shares in the last quarter. Finally, Scalar Gauge Management LLC grew its stake in shares of Enfusion by 21.8% in the 2nd quarter. Scalar Gauge Management LLC now owns 613,513 shares of the company’s stock valued at $5,227,000 after purchasing an additional 110,000 shares during the period. Institutional investors own 81.05% of the company’s stock.

Insiders Place Their Bets

In other news, COO Neal Pawar sold 21,801 shares of Enfusion stock in a transaction on Monday, December 2nd. The stock was sold at an average price of $10.03, for a total value of $218,664.03. Following the completion of the sale, the chief operating officer now directly owns 1,143,544 shares of the company’s stock, valued at approximately $11,469,746.32. This trade represents a 1.87 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CFO Bradley Herring sold 24,443 shares of the business’s stock in a transaction on Friday, December 20th. The stock was sold at an average price of $10.61, for a total value of $259,340.23. Following the sale, the chief financial officer now owns 270,503 shares of the company’s stock, valued at approximately $2,870,036.83. The trade was a 8.29 % decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders sold 58,041 shares of company stock valued at $597,367. Insiders own 36.44% of the company’s stock.

Enfusion Stock Up 0.9 %

Shares of NYSE ENFN opened at $10.91 on Thursday. Enfusion, Inc. has a 12-month low of $7.52 and a 12-month high of $11.38. The firm’s 50-day simple moving average is $10.22 and its 200 day simple moving average is $9.25. The company has a market cap of $1.40 billion, a price-to-earnings ratio of 272.82, a price-to-earnings-growth ratio of 3.98 and a beta of 0.95.

Analysts Set New Price Targets

Several brokerages recently commented on ENFN. Stifel Nicolaus boosted their price target on Enfusion from $11.00 to $13.00 and gave the company a “buy” rating in a research note on Wednesday, December 18th. Piper Sandler lifted their price objective on Enfusion from $10.00 to $11.50 and gave the company a “neutral” rating in a report on Monday, December 23rd. Finally, William Blair reaffirmed a “market perform” rating on shares of Enfusion in a report on Monday. Three analysts have rated the stock with a sell rating, two have assigned a hold rating and two have issued a buy rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Hold” and an average target price of $10.25.

Enfusion Company Profile

Enfusion, Inc provides software-as-a-service solutions for investment management industry in the United States, Europe, the Middle East, Africa, and the Asia Pacific. The company provides Portfolio Management System, which generates a real-time investment book of record that consists of valuation and risk tools, which allows users to analyze aggregated or decomposed portfolio data for chief investment officers (CIOs) and portfolio managers; and Order and Execution Management System that enables portfolio managers, traders, compliance teams, and analysts to electronically communicate trade orders for a variety of asset classes, manage trade orders, and systemically enforce trading regulations and internal guidelines.